Analysis of Influencing Factors of High-Order Aberrations of SMILE With Lenticule Retained
1 other identifier
observational
33
1 country
1
Brief Summary
Analysis of Influencing Factors of High-Order Aberrations of SMILE with Lenticule Retained
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P25-P50 for all trials
Started Oct 2024
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
October 31, 2024
CompletedFirst Submitted
Initial submission to the registry
January 26, 2025
CompletedFirst Posted
Study publicly available on registry
February 3, 2025
CompletedPrimary Completion
Last participant's last visit for primary outcome
October 31, 2026
ExpectedStudy Completion
Last participant's last visit for all outcomes
October 31, 2026
April 22, 2026
October 1, 2025
2 years
January 26, 2025
April 21, 2026
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Δ Higher-order Aberration
Preoperative and postoperative Higher-order aberration difference obtained from wavefront aberrations map of corneal topography in Pentacam measurement.
Day 90
Study Arms (2)
lenticule retained group
Non-lenticule retained group
Eligibility Criteria
Each subject must have complete surgical video recordings and medical records.
You may qualify if:
- Age ≥ 18 years, gender unrestricted;
- Equivalent spherical refraction ≤ -10.0D, corrected distance visual acuity ≥ 1.0, myopia stable for ≥ 2 years, and no contact lens wear for at least 2 weeks;
- The patient voluntarily participates in this study, signs the informed consent form, and agrees to follow up according to the study plan;
- Predicted postoperative residual corneal stromal thickness ≥ 280 micrometers.
You may not qualify if:
- Subclinical keratoconus, keratoconus, moderate to severe corneal opacities or scars, and other ocular conditions;
- Diabetes, keloid-prone constitution, autoimmune and connective tissue diseases, etc.;
- Severe mental disorders such as generalized anxiety disorder, panic disorder, depression, schizophrenia, and bipolar disorder; inability to cooperate with physicians;
- Refusal to participate in the study.
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
The Second Affiliated Hospital of Nanchang University
Nanchang, Jiangxi, 330000, China
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Central Study Contacts
Study Design
- Study Type
- observational
- Observational Model
- OTHER
- Time Perspective
- CROSS SECTIONAL
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Associate research fellow; Attending physician
Study Record Dates
First Submitted
January 26, 2025
First Posted
February 3, 2025
Study Start
October 31, 2024
Primary Completion (Estimated)
October 31, 2026
Study Completion (Estimated)
October 31, 2026
Last Updated
April 22, 2026
Record last verified: 2025-10
Data Sharing
- IPD Sharing
- Will not share